Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

23 févr. 2026 08h30 HE | Source: Sutro Biopharma, Inc.

Sutro Biopharma Announces Participation at the 16th World ADC London Summit

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
23 févr. 2026 08h00 HE | Source: Artios Pharma

Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer

Artios receives FDA Fast Track designation for DNA polymerase theta (Polθ) inhibitor ART6043 for treatment of gBRCA-mutated HER2-negative breast cancer
20 févr. 2026 08h30 HE | Source: PDS Biotechnology Corporation

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
19 févr. 2026 10h48 HE | Source: Research and Markets

Claudin 18.2-Targeted Immunotherapy Pipeline Market Research Report 2026: an Up-to-date Competitor Evaluation in the Field of Therapy Candidates in Research and Development

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Claudin 18.2-Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
19 févr. 2026 10h14 HE | Source: Research and Markets

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Market Review 2025: Regional, Phase, Sponsor & Enrollment Analysis with G7 & E7 Coverage and Five-Year Trend Review

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Gastroesophageal (GE) Junction Carcinomas - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's...
19 févr. 2026 09h39 HE | Source: Research and Markets

Cancer & Antibody Conjugates Patent Landscape Analysis 2025: 3761 Patent Families - IP Trends, Including Time Evolution of Published Patents and Countries of Patent Filings

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Cancer & Antibody Conjugates Patent Landscape Analysis 2025" report has been added to ResearchAndMarkets.com's offering.Key Features: PDF >...
19 févr. 2026 09h00 HE | Source: Broadcom Inc.

Broadcom Introduces Industry’s First 6G Digital Front-End SoC for Massive MIMO

PALO ALTO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Broadcom Inc. (NASDAQ: AVGO), a global technology leader that designs, develops and supplies semiconductor and infrastructure software solutions,...
18 févr. 2026 09h05 HE | Source: Akari Therapeutics Plc

Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

TAMPA, Fla. and LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel...
18 févr. 2026 07h30 HE | Source: Crescent Biopharma, Inc.

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated...
17 févr. 2026 16h05 HE | Source: Kyntra Bio

Kyntra Bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company’s management will participate in the following investor...

Page précédente

Page suivante